Magnetic Resonance Perfusion and Permeability Imaging in Brain Tumors

Neuroimaging Clinics of North America

Volumn 19, Issue 4, 2009, Pages 527-557

  Lacerda, Saulo ^a,b   Law, Meng ^c  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b HOSPITAL BENEFICÊNCIA PORTUGUESA DE SÃO PAULO   (Brazil)

^c LAC USC MEDICAL CENTER   (United States)

Author keywords

Brain tumors; MR perfusion; MR permeability

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CEDIRANIB; ERLOTINIB; GADOLINIUM; GADOLINIUM PENTETATE; IRINOTECAN; MONOCLONAL ANTIBODY DC101; TEMOZOLOMIDE; VASCULOTROPIN;

ARTIFACT; BLOOD VESSEL PERMEABILITY; BRAIN BLOOD FLOW; BRAIN BLOOD VOLUME; BRAIN PERFUSION; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DRUG MECHANISM; DRUG POTENTIATION; GLIOBLASTOMA; GLIOMA; HUMAN; INDICATOR DILUTION CURVE; INTERMETHOD COMPARISON; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PATIENT MONITORING; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; RADIATION NECROSIS; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; STEADY STATE; STEREOTACTIC BIOPSY; STEREOTACTIC RADIOSURGERY; TREATMENT RESPONSE; TUMOR BLOOD FLOW; TUMOR CLASSIFICATION; TUMOR VASCULARIZATION;

BRAIN NEOPLASMS; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY;

EID: 70549114068     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nic.2009.08.007     Document Type: Review

References (91)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
2. Vajkoczy P., and Menger M.D. Vascular microenvironment in gliomas. J Neurooncol 50 1-2 (2000) 99-108
3. Vajkoczy P., and Menger M.D. Vascular microenvironment in gliomas. Cancer Treat Res 117 (2004) 249-262
4. Dvorak H.F., Brown L.F., Detmar M., et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146 5 (1995) 1029-1039
5. Dvorak H.F., Nagy J.A., Feng D., et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 237 (1999) 97-132
6. Provenzale J.M., Wang G.R., Brenner T., et al. Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. AJR Am J Roentgenol 178 3 (2002) 711-716
7. Roberts H.C., Roberts T.P.L., Brasch R.C., et al. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 21 5 (2000) 891-899
8. Roberts H.C., Roberts T.P., Ley S., et al. Quantitative estimation of microvascular permeability in human brain tumors: correlation of dynamic Gd-DTPA-enhanced MR imaging with histopathologic grading. Acad Radiol 9 Suppl 1 (2002) S151-S155
9. Maia Jr. A.C.M., Malheiros S.M.F., da Rocha A.J., et al. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 26 4 (2005) 777-783
10. Sorensen A.G., and Reimer P. Cerebral MR perfusion imaging: principles and current applications. 152nd edition (2000), Thieme, New York
11. Aronen H.J., Gazit I.E., Louis D.N., et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 191 1 (1994) 41-51
12. Aronen H.J., and Perkio J. Dynamic susceptibility contrast MRI of gliomas. Neuroimaging Clin N Am 12 (2002) 501-523
13. Bruening R., Kwong K.K., Vevea M.J., et al. Echo-planar MR determination of relative cerebral blood volume in human brain tumors: T1 versus T2 weighting. AJNR Am J Neuroradiol 17 5 (1996) 831-840
14. Cha S., Knopp E.A., Johnson G., et al. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 223 1 (2002) 11-29
15. Cha S. Perfusion MR imaging: basic principles and clinical applications. Magn Reson Imaging Clin N Am 11 3 (2003) 403-413
16. Cha S., Johnson G., Wadghiri Y.Z., et al. Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn Reson Med 49 5 (2003) 848-855
17. Law M., Yang S., Wang H., et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 24 10 (2003) 1989-1998
18. Lev M.H., and Rosen B.R. Clinical applications of intracranial perfusion MR imaging. Neuroimaging Clin N Am 9 2 (1999) 309-331
19. Petrella J.R., and Provenzale J.M. MR perfusion imaging of the brain: techniques and applications. Am J Roentgenol 175 1 (2000) 207-219
20. Shin J.H., Lee H.K., Kwun B.D., et al. Using relative cerebral blood flow and volume to evaluate the histopathologic grade of cerebral gliomas: preliminary results. Am J Roentgenol 179 3 (2002) 783-789
21. Sugahara T., Korogi Y., Kochi M., et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 171 6 (1998) 1479-1486
22. Sugahara T., Korogi Y., Shigematsu Y., et al. Value of dynamic susceptibility contrast magnetic resonance imaging in the evaluation of intracranial tumors. Top Magn Reson Imaging 10 2 (1999) 114-124
23. Wong E.T., Jackson E.F., Hess K.R., et al. Correlation between dynamic MRI and outcome in patients with malignant gliomas. Neurology 50 3 (1998) 777-781
24. Wong J.C., Provenzale J.M., and Petrella J.R. Perfusion MR imaging of brain neoplasms. Am J Roentgenol 174 4 (2000) 1147-1157
25. Law M., Young R., Babb J., et al. Comparing perfusion metrics obtained from a single compartment versus pharmacokinetic modeling methods using dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 27 9 (2006) 1975-1982
26. Zierler K.L. Circulation times and the theory of indicator-dilution methods for determining blood flow and volume. Handbook of physiology (1962), Williams & Wilkins, Baltimore (MD) 585-615
27. Johnson G., Wetzel S.G., Cha S., et al. Measuring blood volume and vascular transfer constant from dynamic, T(2)*-weighted contrast-enhanced MRI. Magn Reson Med 51 5 (2004) 961-968
28. Tofts P.S., Brix G., Buckley D.L., et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusible tracer: standardized quantities and symbols. J Magn Reson Imaging 10 3 (1999) 223-232
29. Tofts P.S., and Kermode A.G. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 17 2 (1991) 357-367
30. Rosen B.R., Belliveau J.W., Vevea J.M., et al. Perfusion imaging with NMR contrast agents. Magn Reson Med 14 (1990) 249-265
31. Weisskoff R., Belliveau J., Kwong K., et al. Functional MR imaging of capillary hemodynamics. In: Potchen E. (Ed). Magnetic resonance angiography: concepts and applications (1993), Mosby, St Louis (MO) 473-484
32. Young I.R., Cox I.J., Coutts G.A., et al. Some consideration concerning susceptibility, longitudinal relaxation time constants and motion artifact in vivo human spectroscopy. NMR Biomed 2 (1989) 329-339
33. Schmainda K.M., Rand S.D., Joseph A.M., et al. Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. AJNR Am J Neuroradiol 25 9 (2004) 1524-1532
34. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 1 (2007) 83-95
35. Padhani A.R., and Dzik-Jurasz A. Perfusion MR imaging of extracranial tumor angiogenesis. Top Magn Reson Imaging 15 1 (2004) 41-57
36. Cha S., Yang L., Johnson G., et al. Comparison of microvascular permeability measurements, Ktrans, determined with conventional steady-state T1-weighted and first-pass T2*-weighted MR imaging methods in gliomas and meningiomas. AJNR Am J Neuroradiol 27 2 (2006) 409-417
37. Parks LD, Choma MA, York GE, et al. Correlation of DCE and rCBV values for patients with high grade glial neoplasms. Proceedings of the Radiological Society of North America. Chicago (IL); 2005. p. 346.
38. Li K.L., Zhu X.P., Waterton J., et al. Improved 3D quantitative mapping of blood volume and endothelial permeability in brain tumors. J Magn Reson Imaging 12 2 (2000) 347-357
39. Li K.L., Zhu X.P., Checkley D.R., et al. Simultaneous mapping of blood volume and endothelial permeability surface area product in gliomas using iterative analysis of first-pass dynamic contrast enhanced MRI data. Br J Radiol 76 901 (2003) 39-51
40. Cha S. Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol 27 3 (2006) 475-487
41. Boxerman J.L., Schmainda K.M., and Weisskoff R.M. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 27 4 (2006) 859-867
42. Paulson E.S., and Schmainda K.M. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology 249 2 (2008) 601-613
43. Burger P.C. Classification, grading, and patterns of spread of malignant gliomas. In: Apuzzo (Ed). Neurosurgical topics: malignant cerebral glioma (1990), America Association of Neurological Surgeons, Park Ridge (IL) 3-17
44. Daumas-Duport C., Beuvon F., Varlet P., et al. [Gliomas: WHO and Sainte-Anne Hospital classifications]. Ann Pathol 20 5 (2000) 413-428
45. Kleihues P., Soylemezoglu F., Schauble B., et al. Histopathology, classification, and grading of gliomas. Glia 15 3 (1995) 211-221
46. Kleihues P., and Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncol 1 1 (1999) 44-51
47. Kleihues P., and Cavanee P. WHO classification of tumors: pathology and genetic of tumors of the nervous system (2000), IARC Press, Lyon
48. Ringertz J. Grading of gliomas. Acta Pathol Microbiol Scand 27 (1950) 51-64
49. Coons S.W., Johnson P.C., Scheithauer B.W., et al. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79 7 (1997) 1381-1393
50. Gilles F.H., Brown W.D., Leviton A., et al. Limitations of the World Health Organization classification of childhood supratentorial astrocytic tumors. Children Brain Tumor Consortium. Cancer 88 6 (2000) 1477-1483
51. Jackson R.J., Fuller G.N., Abi-Said D., et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-oncol 3 3 (2001) 193-200
52. Law M., Young R.J., Babb J.S., et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR Imaging 10.1148/radiol.2472070898. Radiology 247 2 (2008) 490-498
53. Yang D., Korogi Y., Sugahara T., et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical- shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI. Neuroradiology 44 8 (2002) 656-666
54. Law M., Yang S., Babb J.S., et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 25 5 (2004) 746-755
55. Lupo J.M., Cha S., Chang S.M., et al. Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. AJNR Am J Neuroradiol 26 6 (2005) 1446-1454
56. Verheul H.M., Voest E.E., and Schlingemann R.O. Are tumours angiogenesis-dependent?. J Pathol 202 1 (2004) 5-13
57. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 6801 (2000) 249-257
58. Kerbel R.S. Tumor angiogenesis. N Engl J Med 358 19 (2008) 2039-2049
59. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3 6 (2003) 401-410
60. Jouanneau E. Angiogenesis and gliomas: current issues and development of surrogate markers. Neurosurgery 62 1 (2008) 31-50 [discussion: 50-2]
61. Jain R.K., di Tomaso E., Duda D.G., et al. Angiogenesis in brain tumours. Nat Rev Neurosci 8 8 (2007) 610-622
62. Danchaivijitr N., Waldman A.D., Tozer D.J., et al. Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? 10.1148/radiol.2471062089. Radiology 247 1 (2008) 170-178
63. Martin A.J., Liu H., Hall W.A., et al. Preliminary assessment of turbo spectroscopic imaging for targeting in brain biopsy. AJNR Am J Neuroradiol 22 5 (2001) 959-968
64. Kelly P.J., Daumas-Duport C., Kispert D.B., et al. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 66 6 (1987) 865-874
65. Hu L.S., Baxter L.C., Smith K.A., et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol (2008)
66. Sugahara T., Korogi Y., Tomiguchi S., et al. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 21 5 (2000) 901-909
67. Essig M., Waschkies M., Wenz F., et al. Assessment of brain metastases with dynamic susceptibility-weighted contrast-enhanced MR Imaging: initial results 10.1148/radiol.2281020298. Radiology 228 1 (2003) 193-199
68. Fuss M., Wenz F., Scholdei R., et al. Radiation-induced regional cerebral blood volume (rCBV) changes in normal brain and low-grade astrocytomas: quantification and time and dose-dependent occurrence. Int J Radiat Oncol Biol Phys 48 1 (2000) 53-58
69. Wenz F., Rempp K., Hess T., et al. Effect of radiation on blood volume in low-grade astrocytomas and normal brain tissue: quantification with dynamic susceptibility contrast MR imaging. Am J Roentgenol 166 1 (1996) 187-193
70. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 10 (2005) 987-996
71. Brandes A.A., Franceschi E., Tosoni A., et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26 13 (2008) 2192-2197
72. Brandes A.A., Tosoni A., Spagnolli F., et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro-oncol 10 3 (2008) 361-367
73. Brandsma D., Stalpers L., Taal W., et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9 5 (2008) 453-461
74. de Wit M.C., de Bruin H.G., Eijkenboom W., et al. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63 3 (2004) 535-537
75. Chamberlain M.C., Glantz M.J., Chalmers L., et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82 1 (2007) 81-83
76. de Groot J.F., and Yung W.K. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J 14 5 (2008) 279-285
77. de Gramont A., and Van Cutsem E. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 69 Suppl 3 (2005) 46-56
78. Fine H.A. Promising new therapies for malignant gliomas. Cancer J 13 6 (2007) 349-354
79. Vredenburgh J.J., Desjardins A., Herndon II J.E., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13 4 (2007) 1253-1259
80. Wong E.T., Hess K.R., Gleason M.J., et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17 8 (1999) 2572-2578
81. Pope W.B., Lai A., Nghiemphu P., et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy 10.1212/01.wnl.0000208958.29600.87. Neurology 66 8 (2006) 1258-1260
82. Quarles C.C., and Schmainda K.M. Assessment of the morphological and functional effects of the anti-angiogenic agent SU11657 on 9L gliosarcoma vasculature using dynamic susceptibility contrast MRI. Magn Reson Med 57 4 (2007) 680-687
83. Buie L.W., and Valgus J. Bevacizumab: a treatment option for recurrent glioblastoma multiforme. Ann Pharmacother 42 10 (2008) 1486-1490
84. Gerstner E.R., Sorensen A.G., Jain R.K., et al. Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas. Curr Opin Neurol 21 6 (2008) 728-735
85. Cha S., Knopp E.A., Johnson G., et al. Dynamic, contrast-enhanced T2*-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol 21 5 (2000) 881-890
86. Rubenstein J.L., Kim J., Ozawa T., et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2 4 (2000) 306-314
87. Kunkel P., Ulbricht U., Bohlen P., et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61 18 (2001) 6624-6628
88. Haas-Kogan D.A., Prados M.D., Tihan T., et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97 12 (2005) 880-887
89. Akella N.S., Twieg D.B., Mikkelsen T., et al. Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial. J Magn Reson Imaging 20 6 (2004) 913-922
90. Wetzel S.G., Cha S., Johnson G., et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 224 3 (2002) 797-803
91. Caseiras G.B., Thornton J.S., Yousry T., et al. Inclusion or exclusion of intratumoral vessels in relative cerebral blood volume characterization in low-grade gliomas: does it make a difference?. AJNR Am J Neuroradiol 29 6 (2008) 1140-1141